The Supreme Court in Amgen v. Sanofi affirmed the invalidation of Amgen's antibody patents for lack of enablement. The patents at issue claimed "the entire genus" of antibodies capable of (1) binding specific amino acid...more
10/1/2025
/ Amgen ,
Artificial Intelligence ,
Biotechnology ,
Enablement Inquiries ,
Intellectual Property Protection ,
Life Sciences ,
Machine Learning ,
Patent Litigation ,
Patent Prosecution ,
Patents ,
Pharmaceutical Patents ,
Research and Development
On January 18, 2024, the USPTO rejected a "contingent" terminal disclaimer filed by Acadia Pharmaceuticals Inc. (Acadia) for a patent it owns that is being challenged in a pending litigation as invalid for obviousness-type...more
1/25/2024
/ Abbreviated New Drug Application (ANDA) ,
Obviousness ,
Obviousness-Type Double Patenting (ODP) ,
Orange Book ,
Patent Litigation ,
Patent Term Adjustment ,
Patent Term Extensions ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
USPTO
On January 10, 2024, the United States Patent and Trademark Office (USPTO) issued "Guidelines for Assessing Enablement in Utility Applications and Patents in View of the U.S. Supreme Court Decision in Amgen Inc. et al. v....more